Cellares Selected for FDA’s Manufacturing PreCheck Pilot as Only Cell Therapy Platform
Event summary
- Cellares accepted into FDA’s inaugural Manufacturing PreCheck Pilot Program, one of seven companies nationwide and the only cell therapy platform selected.
- Program offers early FDA engagement for facility design, quality systems, and manufacturing process validation before product applications are filed.
- Selection follows Cellares’ Advanced Manufacturing Technology (AMT) designation and IND Amendment clearance for active clinical manufacturing on its Cell Shuttle platform.
- Cellares aims to reduce U.S. dependence on foreign pharmaceutical manufacturing with automated, domestic cell therapy production capacity.
The big picture
Cellares’ selection underscores the FDA’s push to strengthen domestic pharmaceutical supply chains, aligning with broader U.S. policy goals to reduce reliance on foreign manufacturing. The PreCheck program’s structured pre-operational reviews could accelerate Cellares’ path to commercial readiness, lowering CMC risk for drug sponsors and setting a new standard for automated cell therapy production.
What we're watching
- Regulatory Benchmarking
- Whether Cellares can sustain its position as the regulatory benchmark for automated cell therapy manufacturing in the U.S.
- Commercialization Timelines
- The pace at which Cellares advances its network of GMP IDMO Smart Factories toward commercial-scale production.
- Sponsor Adoption
- How the PreCheck validation will influence drug sponsors’ decisions to partner with Cellares for cell therapy development and manufacturing.
Related topics